Articles

The agency sent a warning letter to Acella Pharmaceuticals detailing CGMP violations and failures to oversee contract manufacturers.

Georgia Facility Receives FDA Warning Letter

The agency sent a warning letter after an inspection of the company’s Sangareddy District, India found inadequate cleaning procedures.

FDA Sends Mylan Warning Letter

Negotiations for a final advance purchase agreement where the Government of Canada purchases the vaccine candidate on a not-for-profit basis for emergency pandemic use are underway. 

J&J to Supply the Government of Canada with Doses of its COVID-19 Vaccine Candidate

The vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval.

Moderna in Discussions to Supply Japan with Doses of its COVID-19 Vaccine Candidate

The facility offers office, production, sampling, and warehouse space and delivers products to all major global markets.

TriRx to Acquire Merck’s MSD Sante Animale Manufacturing Facility 

Novavax and the Government of Canada will finalize an advanced purchase agreement under which Novavax will supply doses of NVX-CoV2373 to Canada beginning in the second quarter of 2021.

Novavax to Supply Canada with Doses of its COVID-19 Vaccine Candidate 

The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

Bilim, H&T Presspart, and Hovione Partner to Bring Asthma Product to the Turkish Market

Oxford Biomedica will reserve capacity for AstraZeneca in three of its manufacturing suites in its new commercial manufacturing center, Oxbox, for 18 months. 



Oxford Biomedica Collaborates with AstraZeneca for COVID-19 Vaccine Candidate Manufacturing

The new facility, located in Lenexa, KS, will rapidly expand production of viral transport media.

Thermo Fisher Opens New Manufacturing Site for COVID-19 Sample Collection

The acquisition will expand Nestlé’s portfolio with access to Aimmune’s Palforzia, the first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children.

News